Surveying the Xenium probe-based in situ sequencing and imaging data, we found high agreement between three cell type markers (ERBB2-tumor, PTPRC-immune, and PDGFRA-stroma) and our CTA outcomes, suggesting its robustness for detecting FFPE sections as well (Supplementary Fig. 2). This evidence concerns the gene PTPRC and neoplasm.